Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEPARP7-IN-16freebaseCat.No.:HY-156419ACASNo.:2136325-05-6分?式:C??H??FN?O?分?量:466.5作?靶點(diǎn):PARP作?通路:CellCycle/DNADamage;Epigenetics儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:33.33mg/mL(71.45mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.1436mL10.7181mL21.4362mL5mM0.4287mL2.1436mL4.2872mL10mM0.2144mL1.0718mL2.1436mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(5.36mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(5.36mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(5.36mM);ClearsolutionBIOLOGICALACTIVITY?物活性PARP7-IN-16freebasePARP7-IN-16(HY-156419)的游離態(tài)形式。PARP7-IN-16freebase選擇性和具有?服活性的PARP-1/2/7抑制劑，IC50值分別為0.94，0.87和0.21nM。PARP7-IN-16可?于乳腺癌和前列腺癌的研究。IC50&TargetPARP7PARP2PARP10.21nM(IC50)0.87nM(IC50)0.94nM(IC50)REFERENCES[1].ZhouJ,et,al.DiscoveryofQuinazoline-2,4(1H,3H)-dioneDerivativesContainingaPiperizinoneMoietyasPotentPARP-1/2Inhibitors─Design,Synthesis,InVivoAntitumorActivity,andX-rayCrystalStructureAnalysis.JMedChem.2023Oct26;66(20):14095-14115.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;